Cite
PCSK9 inhibition ameliorates experimental autoimmune myocarditis by reducing Th17 cell differentiation through LDLR/STAT-3/ROR-γt pathway.
MLA
Yu, Miao, et al. “PCSK9 Inhibition Ameliorates Experimental Autoimmune Myocarditis by Reducing Th17 Cell Differentiation through LDLR/STAT-3/ROR-Γt Pathway.” International Immunopharmacology, vol. 124, Nov. 2023, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.intimp.2023.110962.
APA
Yu, M., Tang, W., Liang, W., Xie, B., Gao, R., Ding, P., Gu, X., Wang, M., Wen, S., & Sun, P. (2023). PCSK9 inhibition ameliorates experimental autoimmune myocarditis by reducing Th17 cell differentiation through LDLR/STAT-3/ROR-γt pathway. International Immunopharmacology, 124, N.PAG. https://doi.org/10.1016/j.intimp.2023.110962
Chicago
Yu, Miao, Wenjing Tang, Wei Liang, Baikang Xie, Ran Gao, Peiwu Ding, Xiaoying Gu, Min Wang, Shuang Wen, and Peng Sun. 2023. “PCSK9 Inhibition Ameliorates Experimental Autoimmune Myocarditis by Reducing Th17 Cell Differentiation through LDLR/STAT-3/ROR-Γt Pathway.” International Immunopharmacology 124 (November): N.PAG. doi:10.1016/j.intimp.2023.110962.